Focus Partners Wealth
SABS icon

Focus Partners Wealth’s SAB Biotherapeutics SABS Stock Holding History

Focus Partners Wealth’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,036
Closed -$53.8K – 2944
2026
Q1 		$53.8K Sell
14,036
-5,165
-27% -$20.6K ﹤0.01% 2575
2025
Q4 		$71.8K Buy
+19,201
New +$63.2K ﹤0.01% 2583

Other funds holding SABS

Caligan Partners
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Commodore Capital
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Focus Partners Wealth's SABS Position: Q2 2026 in Review

Focus Partners Wealth sold out of SAB Biotherapeutics (SABS) in Q2 2026, closing a stake of 14,036 shares — an estimated $53.8K sold.

Focus Partners Wealth first reported a position in SABS in Q4 2025 and held it in 2 quarters. The position peaked at $71.8K in Q4 2025. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Focus Partners Wealth reported no remaining SAB Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Focus Partners Wealth sold 14,036 SAB Biotherapeutics shares in Q2 2026, an estimated $53.8K.
  • Focus Partners Wealth first reported a position in SAB Biotherapeutics in Q4 2025 and held it in 2 quarters.
  • Focus Partners Wealth's SAB Biotherapeutics position peaked at $71.8K in Q4 2025.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.